$5.21
0.76% yesterday
Nasdaq, Apr 07, 10:01 pm CET
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Fennec Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation

Fennec Pharmaceuticals Inc. Classifications & Recommendation:

Buy
100%

Fennec Pharmaceuticals Inc. Price Target

Target Price $12.60
Price $5.21
Potential
Number of Estimates 5
5 Analysts have issued a price target Fennec Pharmaceuticals Inc. 2026 . The average Fennec Pharmaceuticals Inc. target price is $12.60. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend Fennec Pharmaceuticals Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Fennec Pharmaceuticals Inc. stock has an average upside potential 2026 of . Most analysts recommend the Fennec Pharmaceuticals Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 47.54 47.11
123.72% 0.91%
EBITDA Margin 5.41% 24.84%
109.00% 359.49%
Net Margin -1.16% 3.97%
98.51% 442.78%

5 Analysts have issued a sales forecast Fennec Pharmaceuticals Inc. 2025 . The average Fennec Pharmaceuticals Inc. sales estimate is

$47.1m
Unlock
. This is
0.91% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$62.3m 31.09%
Unlock
, the lowest is
$36.3m 23.71%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $47.5m 123.72%
2025
$47.1m 0.91%
Unlock
2026
$80.5m 70.89%
Unlock
2027
$103m 27.93%
Unlock
2028
$116m 12.26%
Unlock
2029
$157m 35.46%
Unlock

1 Analyst has issued an EBITDA forecast Fennec Pharmaceuticals Inc. 2025 . The average Fennec Pharmaceuticals Inc. EBITDA estimate is

$11.7m
Unlock
. This is
355.25% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$11.7m 355.25%
Unlock
, the lowest is
$11.7m 355.25%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $2.6m 120.13%
2025
$11.7m 355.25%
Unlock
2026
$28.3m 141.88%
Unlock

EBITDA Margin

2024 5.41% 109.00%
2025
24.84% 359.49%
Unlock
2026
35.15% 41.51%
Unlock

5 Fennec Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Fennec Pharmaceuticals Inc. net profit estimate is

$1.9m
Unlock
. This is
213.21% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$15.1m 1,016.58%
Unlock
, the lowest is
$-7.7m 366.76%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-551k 96.67%
2025
$1.9m 439.63%
Unlock
2026
$27.9m 1,393.05%
Unlock
2027
$49.3m 76.50%
Unlock
2028
$62.8m 27.37%
Unlock
2029
$94.7m 50.87%
Unlock

Net Margin

2024 -1.16% 98.51%
2025
3.97% 442.78%
Unlock
2026
34.68% 773.55%
Unlock
2027
47.85% 37.98%
Unlock
2028
54.29% 13.46%
Unlock
2029
60.47% 11.38%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.02 0.07
96.67% 450.00%
P/E 76.62
EV/Sales 2.87

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast for earnings per share. The average Fennec Pharmaceuticals Inc. EPS is

$0.07
Unlock
. This is
216.67% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.55 1,016.67%
Unlock
, the lowest is
$-0.28 366.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.02 96.67%
2025
$0.07 450.00%
Unlock
2026
$1.01 1,342.86%
Unlock
2027
$1.79 77.23%
Unlock
2028
$2.28 27.37%
Unlock
2029
$3.44 50.88%
Unlock

P/E ratio

Current -88.31 398.93%
2025
76.62 186.76%
Unlock
2026
5.14 93.29%
Unlock
2027
2.91 43.39%
Unlock
2028
2.29 21.31%
Unlock
2029
1.51 34.06%
Unlock

Based on analysts' sales estimates for 2025, the Fennec Pharmaceuticals Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.84 80.29%
2025
2.87 1.06%
Unlock
2026
1.68 41.48%
Unlock
2027
1.31 21.83%
Unlock
2028
1.17 10.92%
Unlock
2029
0.86 26.18%
Unlock

P/S ratio

Current 3.02 77.82%
2025
3.05 0.92%
Unlock
2026
1.79 41.48%
Unlock
2027
1.40 21.83%
Unlock
2028
1.24 10.92%
Unlock
2029
0.92 26.18%
Unlock

Current Fennec Pharmaceuticals Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Dec 17 2024
HC Wainwright & Co.
Locked
Locked
Locked Aug 22 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 17 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 22 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today